61995-20-8

Usage

Uses

Used in Pharmaceutical Industry:
1-N-Cbz-3-piperidone is used as a synthetic intermediate for the development of potential dopamine agonists. These agonists are crucial in the treatment of various neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). 1-N-Cbz-3-piperidone's unique structure allows for the creation of 6-substituted 7-methyl-1,4-dioxa-7-azaspiro[4.5]decanes, which exhibit promising pharmacological properties.
In the synthesis process, 1-N-Cbz-3-piperidone acts as a building block, enabling the formation of complex molecular structures with potential therapeutic applications. Its use in the pharmaceutical industry is primarily focused on the development of novel drugs that can effectively target and modulate dopamine receptors, leading to improved treatment options for patients suffering from the aforementioned conditions.

InChI:InChI=1/C13H15NO3/c15-12-7-4-8-14(9-12)13(16)17-10-11-5-2-1-3-6-11/h1-3,5-6H,4,7-10H2

Upstream product

• 40114-49-6 1-benzyl-3-piperidone 
• 501-53-1 benzyl chloroformate 
• 95798-22-4 3-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 61644-00-6 piperidin-3-one hydrochloride 
• 50717-82-3 piperidin-3-one 
• 6859-99-0 3-hydroxypiperazine 
• 5105-78-2 4-(benzyloxycarbonylamino)butyric acid 
• 50606-58-1 N-benzyl-3-piperidinone hydrochloride 

Downstream Products

• 149108-73-6 Benzyl 1,2,3,4-tetrahydro-5-<(trifluoromethyl)sulfonyloxy>-pyridine-1-carboxylate 
• 138163-15-2 3-methylenepiperidine-1-carboxylic acid benzyl ester 
• 227959-50-4 3-(ethoxy-methyl-phosphinoyl)-3-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 227959-44-6 3-(diethoxymethyl-ethoxy-phosphinoyl)-3-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 199102-72-2 2-amino-7-benzyloxycarbonyl-3-(3,4-dimethoxybenzoyl)-4,5,6,7-tetrahydrothieno[2,3-b]pyridine 
• 199102-09-5 ethyl 2-(diethylaminomethyl)-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-b']dipyridine-3-carboxylate 
• 199102-76-6 7-chloromethyl-5-(3,4-dimethoxy-phenyl)-3,4-dihydro-2H-thieno[2,3-b;5,4-b']dipyridine-1,6-dicarboxylic acid 1-benzyl ester 6-ethyl ester 
• 199102-06-2 ethyl 8-benzyloxycarbonyl-2-diethylaminomethyl-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-b']dipyridine-3-carboxylate 
• 227959-52-6 3-(ethoxy-methyl-phosphinoyl)-piperidine-1-carboxylic acid benzyl ester 
• 227959-51-5 oxalic acid 1-benzyloxycarbonyl-3-(ethoxy-methyl-phosphinoyl)-piperidin-3-yl ester methyl ester 
• 227959-48-0 3-(diethoxymethyl-ethoxy-phosphinoyl)-piperidine-1-carboxylic acid benzyl ester 
• 227959-46-8 oxalic acid 1-benzyloxycarbonyl-3-(diethoxymethyl-ethoxy-phosphinoyl)-piperidin-3-yl ester methyl ester 
• 276872-92-5 N-(benzyloxycarbonyl)-2-phenylmethyl-3-piperidone 
• 870859-10-2 benzyl 3-[(R)-1-(naphthalen-1-yl)ethylamino]-piperidine-1-carboxylate 

Relevant academic research and scientific papers

AROMATIC COMPOUND

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to phenyl amino pyrimidine bicyclic compounds formula (I) which are inhibitors of protein kinases including JAK kinases. In particular the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

BRUTON'S TYROSINE KINASE INHIBITORS

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF

The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensiing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, -CH 2 -, -CO- , - (CH 2 ) m -CO- , -CH (R 2 ) -CO-, - (CH 2 ) p -Y-(C(R 3 ) (R 4 )) q -CO-, -NH-CO- or -N(R 5 ) -CO-; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: -O- or -SO 2 -; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is -CH 2 - or -CO-, R 1 is not naphthyl.

Piperididinyl and N-amidinopiperidinyl derivatives

This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds

Intramolecular N-H insertion of α-diazocarbonyls catalyzed by Cu(acac)2: An efficient route to derivatives of 3-oxoazetidines, 3-oxopyrrolidines and 3-oxopiperidines

Cu(acac)2 was found to be an efficient catalyst for the intramolecular N-H insertion by carbenoids. The competitive intramolecular C-H insertion by carbenoids is not a problem in the diazo decomposition reaction with Cu(acac)2 as catalyst. The reaction provided derivatives of 3-oxoazetidine, 3-oxopyrrolidine and 3-oxopiperidine in moderate to good yields.

Piperidinyl-3-phosphinic acids as novel uptake inhibitors of the neurotransmitter γ-aminobutyric acid (GABA)

Piperidinyl-3-phosphinic acid 2, piperidinyl-3-methylphosphinic acid 3 and N-(4,4-diphenyl-3-butenyl)-piperidinyl-3-phosphinic acid 4 have been synthesized as bioisosteres of the corresponding amino carboxylic acids, which are potent and specific GABA-uptake inhibitors. The novel amino phosphinic acids were tested for their GABA-uptake inhibitory activity and 2 and 4 were identified as the first phosphinic acid based GABA-uptake inhibitors. The methylphosphinic acid 3 was found to be inactive.

A convenient synthesis of functionalized 8- and 9-aza-1-oxaspiro[5.5]undecanes

2-Hydroxy-8-(or 9-)aza-1-oxaspiro[5.5]undec-3-en-5-ones derived from their corresponding 2-furfuryl alcohols were used as key intermediates for the convenient synthesis of several novel 8- and 9-aza-1-oxaspiro[5.5]undecane derivatives.

A CONVENIENT APPROACH TO THE N-SUBSTITUTED AMINO DIENES, N-BENZYL-5-ETHENYL-3,4-DIHYDROPYRIDIN-2-ONE AND N-CBZ-5-ETHENYL-1,2,3,4-TETRAHYDROPYRIDINE

A synthesis of N-substituted amino dienes (1a) and (1b) is described according to two different approaches. 1a is obtained trough condensation of methyl 4-formyl-6-selenophenylhexanoate (4) with benzylamine followed by oxidation and elimination; 1b is for

Analogues of the low-efficacy partial GABAA agonist 4-PIOL. Syntheses and in vitro pharmacological studies

4-PIOL (3-hydroxy-5-(4-piperidyl)isoxazole) is a low-efficacy GABAA agonist showing a dominating GABAA antagonist profile.Three dihydro analogues of 4-PIOL were synthesized, including (RS)-3-hydroxy-5-(4-piperidyl)-2-isoxazoline (1).The synthesis of 1 was based on a regioselective 1,3-dipolar cyclo-addition reaction between 1-benzyloxycarbonyl-4-vinylpiperidine (7) and bromonitrile oxide, prepared in situ from dibromoformoxime.Furthermore, the spiro analogues of 1 3-hydroxy-1-oxa-2,8-diazaspirodec-2-ene (2) and (RS)-3-hydroxy-1-oxa-2,7-diazaspirodec-2-ene (3) were synthesized regiospecifically via cycloaddition of bromonitrile oxide to the N-benzyloxycarbonyl-protected forms of 4-methylenepiperidine (11) and 3-methylenepiperidine (15) respectively.In contrast to 4-PIOL, none of the new compounds 1-3 showed detectable effects on the binding of 3H-GABAA or the subunit-selective GABAA agonist, 3H-THIP, to GABAA receptor sites, and they did not significantly affect the muscimol-stimulated binding of 3H-diazepam to the benzodiazepine site of the GABAA receptor complex.